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Abstract
Background: p16INK4a is a tumor suppressor protein which is induced in cells upon the interaction of high-risk HPV E7 with
the retinoblastoma protein by a positive feedback loop, but cannot exert its suppressing effect. Previous reports suggested
that p16INK4a immunostaining allows precise identification of even small CIN or cervical cancer lesions in biopsies. The
prognostic value of overexpressed p16INK4a in cervical cancer has been evaluated for several years while the results remain
controversial. We performed a systematic review and meta-analysis of studies assessing the clinical and prognostic
significance of overexpression of p16INK4a in cervical cancer.
Methods: Identification and review of publications assessing clinical or prognostic significance of p16INK4a overexpression in
cervical cancer until March 1, 2014. A meta-analysis was performed to clarify the association between p16INK4a
overexpression and clinical outcomes.
Results: A total of 15 publications met the criteria and comprised 1633 cases. Analysis of these data showed that p16INK4a
overexpression was not significantly associated with tumor TNM staging (I+II vs. III+IV) (OR = 0.75, 95% confidence interval
[CI]: 0.35–1.63, P = 0.47), the tumor grade (G1+ G2 vs. G3) (OR= 0.78, 95% CI: 0.39–1.57, P = 0.49), the tumor size (,4 vs. $
4 cm) (OR = 1.10, 95% CI: 0.45–2.69, P = 0.83), or vascular invasion (OR= 1.20, 95% CI: 0.69–2.08, P = 0.52). However, in the
identified studies, overexpression of p16INK4a was highly correlated with no lymph node metastasis (OR= 0.51, 95% CI: 0.28–
0.95, P = 0.04), increased overall survival (relative risk [RR]: 0.42, 95% CI: 0.24–0.72, P = 0.002) and increased disease free
survival (RR: 0.60, 95% CI: 0.44–0.82, P = 0.001).
Conclusions: This meta-analysis shows overexpression of p16INK4a in cervical cancer is connected with increased overall and
disease free survival and thus marks a better prognosis.
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Introduction
Cervical cancer is the third most common malignancy in
women worldwide and a leading cause of cancer-related death
in women in developing countries [1]. The relationship between
the development of cervical cancer and persistent infection with
high-risk human papilloma virus (HR-HPV) is well established
[2]. A plethora of research on the development of objective
biomarkers allowing to distinguish the transformation from
productive HPV infections to carcinoma and to predict disease
severity has been performed. The cellular tumor suppressor
protein cyclin-dependent kinase inhibitor 2A (p16INK4a) has
been identified as a biomarker for transforming HPV infections
[3]. It decelerates the cell cycle by inactivating the cyclin-
dependent kinases (CDK4/CDK6) involved in the phosphory-
lation of the retinoblastoma protein (pRb) [4]. This process is
leading to senescence in normal cells. In the presence of the
HR-HPV oncogene E7, p16INK4a transcription is induced by
the histone demethylase KDM6B [5]. HPV E7 expression
causes an acute dependence on KDM6B expression for cervical
cancer cell survival. Thus, the p16INK4A tumor suppressor is a
critical KDM6B downstream transcriptional target and its
expression is critical for cell survival [6].
Over the past decade, several studies have evaluated the
prognostic value of p16INK4a protein expression in cervical cancer
with conflicting results. Some concluded that p16INK4a expression
had no influence on survival [7] while others reported that
p16INK4a expression was predictive of improved survival outcome
for cervical carcinoma [8,9]. In order to evaluate this question, we
conducted a systematic review and meta-analysis to determine the
association between the overexpression of p16INK4a and common
clinical and pathologic features of cervical cancer.
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Materials and Methods
Search strategy
A comprehensive literature search of the electronic databases
PubMed (www.pubmed.com), EMBASE (www.embase.com) and
Wanfang (www.wanfangdata.com.cn) was performed up to March
1, 2014. The following search terms and their combinations were
used: ‘‘cervical cancer,’’ ‘‘cervical carcinoma,’’ ‘‘carcinoma of
cervix’’, ‘‘CDKN2A’’, ‘‘p16’’ and ‘‘p16INK4a’’. The citation lists
associated with all the studies retrieved in the search were used to
identify other potentially relevant publications. Review articles
were also scanned to find additional eligible studies but none could
be identified from the reference lists. The title and abstract of each
study identified in the search was scanned to exclude any clearly
irrelevant publications. The remaining articles were browsed to
determine whether they contained information on the topic of
interest.
Selection criteria
Diagnosis of cervical cancer was proven by histopathological
methods. Studies of p16INK4a expression based on cervical cancer
tissue (after either surgical excision or biopsy sampling) were
included. Studies based on serum or any other kinds of specimen
were excluded. All studies on the correlation of p16INK4a
overexpression with clinicopathological markers and the associa-
tion of p16INK4a overexpression on overall survival (OS) or
disease-free survival (DFS) of cervical cancer patients were
included. For inclusion into the analysis, there was no limitation
on the minimum number of patients of every single study. When
there were multiple articles by the same group based on similar
patients and using same detection methods, only the largest or the
most recent article was included.
Data extraction
Information was carefully extracted from all eligible publica-
tions independently by two of the authors according to the
inclusion criteria listed above. Disagreement was resolved by a
consensus discussion between the two authors. Data tables were
composed to extract all relevant data from texts, tables, and figures
of each included study, including author, publication year, country
of patient’s origin, tumor stage, number of patients, research
technique used, and cutoff value of overexpression of p16INK4a. In
case the prognosis was only plotted as Kaplan-Meier curve in
some articles, the software GetData Graph Digitizer 2.24 (free
software downloaded at http://getdata- graph-digitizer.com) was
applied to digitize and extract the data.
Statistical analysis
The cut-off for p16INK4a –positivity according to stained cells is
given in table 1 for every study included. ORs with 95%
confidence intervals (CI) were used to evaluate the association
between p16INK4a overexpression and clinicopathological factors,
including tumor TMN staging, tumor grade, tumor size, vascular
invasion and lymph node status. To stratify for the analysis, the
following data of p16INK4a overexpression and clinicopathological
factors were combined into single categories with comparable
clinicopathologic relevance: tumor TMN staging (I+II vs. III+IV);
tumor grade (G1+G2 vs. G3); tumor size (,4 vs.$4 cm); vascular
invasion or not; lymph node negative or positive.
The RR with 95% CI was used for assessing the association of
p16INK4a and the survival outcome combined over studies. An
observed OR or RR ,1 implied a better prognosis for the group
with p16INK4a overexpression and would be considered to be
statistically significant if the 95% CI did not exceed 1. The
existence of heterogeneity between studies was evaluated using the
Dersimonian and Laird’s Q test [10]. I2 was used to quantify
heterogeneity and an I2 value .50% was considered to represent
substantial heterogeneity between studies. Relative to fixed-effects
models, random-effects models were used and were more
appropriate for the current study, because of the heterogeneity
visible from the forest plots which often cannot be revealed by the
Q test given its low power. The influence of individual studies on
the summary effect estimate was displayed using the sensitivity
analysis. In addition, funnel plots and the Egger’s test were used to
estimate the possible publication bias [11]. Cochrane Review
Manager, version 5.2 (Cochrane Library, Oxford, UK) was used




A total of 15 publications met the criteria for this analysis [7–
9,12–23] (Fig. 1). The total number of patients was 1633, ranging
from 35 to 275 patients per study. Main characteristics of the
eligible studies are summarized in Table 1 including the cut-off
definition for p16 INK4a positivity. Thirteen articles dealt with
clinicopathological factors. Eight studies determined overall
survival (OS) or disease free survival (DFS). Seven studies only
reported the association between p16INK4a overexpression and
clinicopathological factors without OS or DFS analysis. There was
only one method used to evaluate p16INK4a expression in cervical
cancer specimens i.e. immunohistochemistry (IHC).
Correlation of p16INK4a expression with
clinicopathological parameters
The association between p16INK4a and several clinicopatholog-
ical parameters is illustrated in Figure 2. Overexpression of
p16INK4a was highly correlated with no lymph node metastasis
(OR = 0.51, 95% CI: 0.28–0.95, P = 0.04) (Fig. 2A). However,
overexpression of p16INK4a was not significantly associated with
tumor TNM staging (I+II vs. III+IV) (OR = 0.75, 95% CI: 0.35–
1.63, P = 0.47) (Fig. 2B), the tumor grade (G1+ G2 vs. G3)
(OR = 0.78, 95% CI: 0.39–1.57, P = 0.49)(Fig. 2C), the tumor size
(,4 vs. $4 cm) (OR = 1.10, 95% CI: 0.45–2.69, P = 0.83)
(Fig. 2D), or vascular invasion (OR = 1.20, 95% CI: 0.69–2.08,
P = 0.52) (Fig. 2E).
p16INK4a expression and 5-year survival outcome
Using the methods described above, the OS and/or DFS of 849
patients in 8 studies were analyzed. The main results of this meta-
analysis are shown in Figure 2. Five-year OS rate was extracted
from 5 studies. The meta-analysis of the 5 studies for the
prognostic value of p16INK4a overexpression showed that p16INK4a
overexpression was associated with a favorable OS. This was
obtained from the DerSimonian–Laird random-effects model with
a value of 0.42 (95% CI: 0.24–0.72, P = 0.002) (Fig. 3), although
there was heterogeneity between studies (I2 = 58%, Ph = 0.05). In
fact, 4 out of 5 studies have also concluded p16INK4a expression as
a favorable prognostic factor in cervical cancer patients (Fig. 3A).
p16INK4a expression and DFS in cervical cancer
Meta-analysis of 4 applicable studies showed that p16INK4a
expression was associated with favorable DFS (RR: 0.60, 95% CI:
0.44–0.82, P = 0.001; Fig. 3B). No heterogeneity was observed
between these studies (I2 = 0%, Ph = 0.78).
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Sensitivity analysis
In order to test for a bias introduced by the low numbers of
available eligible publications we performed a sensitivity analysis.
For this a single study involved in the meta-analysis was omitted
for each round of analysis to investigate the influence of the
individual data set of the particular study to the pooled ORs. We
found that the corresponding pooled ORs were not essentially
altered by substraction of any study (data not shown), indicating
that our results were statistically robust.
Publication Bias
Begg’s funnel and Egger’s test were performed to assess the
publication bias in this meta-analysis. The shape of the Funnel
plots did not reveal obvious evidence of asymmetry. Egger’s test
showed no significant publication bias for tumor grade (P = 0.18),
TMN classification (P = 0.835), tumor size (P = 0.851), lymph node
status (P = 0.051), vascular invasion (P = 0.142), DFS (P = 0.602)
and OS (P = 0.624) (Table 2).
Discussion
The p16INK4a protein is a cyclin-dependent kinase inhibitor that
regulates the G1/S cell cycle checkpoint by inactivating cyclin D1-
CDK4/6 complex activity and thereby enhancing pRb activity
and suppressing cell growth [24]. It was shown recently that HPV-
transformed cervical cancer cells are dependent on its expression
and knock down will lead to reduced proliferation [6]. Many IHC-
studies have demonstrated that p16INK4a protein is highly
overexpressed in dysplastic epithelial cells of the uterine cervix
and that it is associated with HR-HPV infection. At the same time
its expression is basal in normal epithelium and benign lesions due
to few spontaneous senescent cells [25]. Furthermore, overexpres-
sion of p16INK4a appears to correlate with the degree of cervical
neoplasia, which may improve the histological diagnosis and hence
the management of cervical lesions [26]. Tsoumpou et al [27]
performed a meta-analysis of 61 published studies on the
correlation of the p16INK4a immunostaining to the degree of
cytological or histological abnormality. They reported that the
proportion of cervical smears overexpressing p16INK4a increased
with the severity of cytological abnormality. In histology only 2%
of normal biopsies and 38% of CIN1 showed diffuse staining for
Figure 1. Literature search strategy and selection of articles. A total of 346 articles were selected for the meta-analysis by browsing the
databases PubMed, Embase and Wanfang, of which 324 were excluded after reviewing the title and abstract, seven articles were excluded after
reviewing the full publications, the reasons for exclusion were: (a) Non-association studies (b) researchers in the article did not use neither
histopathologic analysis nor close clinical and imaging follow-up for at least 6 months, (c) association studies for other diseases (d), non-original
articles, (e) data couldn’t be extracted or (f) repeated data from the same or similar population. Finally, a total of 15 studies with 1633 patients, who
fulfilled all of the inclusion criteria, were considered for the analysis.
doi:10.1371/journal.pone.0106384.g001
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p16INK4a compared to 68% of CIN2 and 82% of CIN3 [27].
Thus, p16INK4a is regarded a surrogate biomarker for cervical
intraepithelial neoplasia.
Recently, the clinical significance of p16INK4a overexpression in
cervical cancer has been reported by many investigators.
However, the results of these reports are still conflicting. To
address the predictive value of p16INK4a overexpression in cervical
cancer, we performed a meta-analysis of the published studies to
obtain a more precise estimation of the above stated association.
This meta-analysis summarizes all currently available and relevant
data on the impact of p16INK4a overexpression on the prognosis of
cervical cancer including 1633 cases. Altogether our results using
the pooled RR of OS indicate that a low p16INK4a expression
indicates a poorer prognosis for patients diagnosed with cervical
cancer than p16INK4a overexpression. Our findings were consis-
tent with the theory that HR-HPV is a triggering factor in the
development of cervical cancer, but would concomitantly induce a
p16INK4a -mediated protection mechanism [28]. The reason is not
clear at present but presumably overexpression of p16INK4a can be
recognized by the immune system as an antigen of naturally low
expressed protein. This p16INK4a protein can eventually initiate an
antitumor response in cervical cancer patients [29].
However, the lack of standardized cut-off points for positive
expression could have led to underestimation of the true
prognostic significance of p16INK4a overexpression. No clear
guidelines are available regarding their use in routine practice
[30]. Tsoumpou et al [27] reviewed 40 publications where 35 used
Klaes’ scoring system. The percentage of p16INK4a positivity of
high grade squamous intraepithelial lesion varied between 44%
and 92%. Thus, a predictive evaluation of the scoring systems to
reach a consensus on the threshold of positivity is needed.
Strong p16INK4a expression is a proven useful surrogate marker
for tumors with transcriptionally active HR-HPV, which is known
to be associated with less genetically altered and less complex
tumors that respond better to therapy and have improved
outcomes. The positivity for p16INK4a has been proposed as a
prognostic marker for a more favorable outcome in head and neck
squamous cell carcinoma and in lung cancer [31,32]. Some
authors have suggested that p16INK4a plays a major role not only
in suppression of cell division but also in suppression of
lymphangiogenesis and lymphatic metastasis [30].
Our analysis is supported by the clinical observations of Riou
et al [33] who reported that HPV-negative cervical cancer patients
had a significantly higher risk of overall relapse and a higher risk of
distant metastatic tumor than HPV-positive patients. Tumors that
lack HR-HPV positivity may have a larger number of mutations in
genes coding for cell cycle regulating proteins to be transformed,
and thus may be more therapy resistant [34]. This is corroborated
by the fact that HR-HPV positive carcinoma generally is more
susceptible to radiochemotherapy than HPV-negative counter-
parts [35].
This meta-analysis has certain limitations that should be
considered when interpreting the results. First, our results are
based on unadjusted estimates. A more precise analysis could be
Figure 2. Forest plot depiction of p16INK4a expression and OR for clinical pathologic features. Clinicopathological parameters
investigated are lymph node status (A), TMN classification (B), tumor grade (C), size of tumor (D), vascular invasion (E). OR with corresponding
confidence intervals are shown.
doi:10.1371/journal.pone.0106384.g002
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conducted using the original individual data sets that, however, are
not available to us. Nevertheless, such an approach would allow
for adjustment by other co-variates including age, ethnicity, family
history, environmental factors, treatment and lifestyle [36].
Second, heterogeneity is a potential problem when interpreting
the results of meta-analyses. We minimized the likelihood of this
problem by performing a careful search for published studies using
explicit criteria for study inclusion, precise data extraction, and
strict data analysis. However, significant heterogeneity between
studies existed in some comparisons. The presence of heteroge-
neity results from differences in many factors, including the age
distribution, lifestyle factors and the standard of the IHC
technique used particularly concerning the positivity threshold.
Third, only published full text studies were included in this meta-
analysis. Non-significant or negative findings may not be published
or only published as abstract at conferences and could therefore
Figure 3. Analysis of p16INK4a expression and survival of cervical cancer patients. Forest plot of RR for OS (A) and DFS (B) among included
studies. Combined RR was calculated by a random mode.
doi:10.1371/journal.pone.0106384.g003
Table 2. Egger’s test of funnel plot asymmetry.
clinicopathological parameters t value df P value
tumor grade 0.59 11 0.18
TMN classification 0.28 10 0.835
tumor size 0.11 5 0.851
lymph node metastasis 1.73 16 0.051
vascular invasion 3.68 4 0.142
disease free survival 0.67 2 0.602
overall survival 0.29 4 0.624
df: deflection.
doi:10.1371/journal.pone.0106384.t002
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not be evaluated. We included data of 1633 patients currently
available in this meta-analysis that should lay the foundation to
perform a larger and prospective study.
In conclusion, despite the limitations of this meta-analysis, our
study suggests that p16INK4A overexpression is significantly
associated with better prognosis in terms of longer DFS and OS
in patients with cervical cancer. Hopefully this analysis will
stimulate further research with rigid criteria and large study
populations to resolve any remaining controversy of the role of
p16INK4A expression for the prognosis of patients with cervical
cancer.
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